Abstracting and Indexing

  • Google Scholar
  • Semantic Scholar
  • CrossRef
  • WorldCat
  • ResearchGate
  • Academia.edu
  • Scilit
  • Baidu Scholar
  • DRJI
  • Microsoft Academic
  • Academic Keys
  • Academia.edu
  • OpenAIRE

Patients at Risk of Pulmonary Fibrosis Post Covid-19: Pulmonary Sequelae and Humoral Response

Author(s): Miriam Hernández Porto, Teresa Delgado, Armando Aguirre-Jaime, María Jose Ramos, Silvia Campos, Orlando Acosta, Ana Belén Llanos, María Lecuona

Background: The COVID-19 pandemic is one of the major public health problems. The aim of this study is to characterize patients hospitalized for COVID-19 pneumonia at risk of pulmonary fibrosis and to know the amount of protective antibodies and their permanence in these patients.

Methods: Follow-up study of the humoral response in hospitalized patients at risk of pulmonary fibrosis post-COVID-19 who were followed up for one year after hospital discharge.

Results: The study included 72 patients, 52 of whom had pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% as mild, 58% as moderate and 36% as severe. After one year follow-up, forty percent had pulmonary sequelae, the most frequent being mild pulmonary fibrosis. All patients presented RBD IgG, 88% IgA after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-COVID-19. There was no difference in RBD IgG level according to COVID-19 severity (P = .441, P = .594).

Conclusions: The amount of RBD IgG is maintained throughout the convalescent phase and could protect against new reinfections in patients at risk of pulmonary fibrosis Post Covid-19. However, it does not seem to predict the development or not of pulmonary fibrosis.

Grant Support Articles

© 2016-2022, Copyrights Fortune Journals. All Rights Reserved!